Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
To evaluate the clinical efficacy and safety of hypofractionation radiotherapy combined with sintilimab，GM-CSF and Fruquintinib in Patients With MSS Metastatic Colorectal Carcinoma (mCRC)
Colorectal Neoplasms
RADIATION: hypofractionation Radiotherapy|DRUG: sintilimab|DRUG: GM-CSF|DRUG: Fruquintinib
Progression-free survival (PFS), Defined as the time from the date of the first dose of treatment to the date of the first documentation of disease progression or death, whichever occurs first.

Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST, 2 years
Objective response rate, Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST, 1 year|Disease Control Rate（DCR）, Disease Control Rate（DCR）according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST, 1 year|Duration of Response(DOR), Duration of Response(DOR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST, 1 year|Overall survival (OS), Defined as the time from the date of the first dose of treatment until the date of death due to any cause., 2 years|Safety:Percentage of Participants With Adverse Events (AEs), Percentage of Participants With Adverse Events (AEs) Number of participants with adverse events occurring up to 30 days after the last administration are evaluated and graded according to the National Cancer Institute Common Terminology Criteria (NCI CTCAE) for Adverse Events, version 5.01, Up to 30 days after the last cycle of per-protocol treatment and 90 days after last dose of treatment
Condition or disease:MSS Metastatic Colorectal Carcinoma (mCRC)

Phase:Phase 2

Intervention/treatment:

Radiation: hypofractionation radiotherapy

Drug: sintilimab, GM-CSF , Fruquintinib